Abstract Number: 2360 • 2015 ACR/ARHP Annual Meeting
The Effectiveness of Tacrolimus in Patients with Interstitial Lung Disease Secondary to Autoimmune Disease
Background/Purpose: Interstitial lung disease (ILD) secondary to connective tissue disease (CTD) is most commonly seen in systemic sclerosis followed by polymyositis and dermatomyositis. Anti-synthetase syndrome…Abstract Number: 2361 • 2015 ACR/ARHP Annual Meeting
Abatacept in the Treatment of Adult Dermatomyositis and Polymyositis: a Randomized, Treatment Delayed-Start Trial
Background/Purpose: The aim of the study was to assess the effects of abatacept, a T cell blocking agent, on disease activity and on muscle biopsy…Abstract Number: 2362 • 2015 ACR/ARHP Annual Meeting
Rituximab in the Treatment of Jo-1 Antibody-Associated Antisynthetase Syndrome: Anti-Ro52 Positivity As a Marker for Severity and Treatment Response
Background/Purpose: Rituximab (RIX) has successfully been used for the treatment of severe Jo-1 antibody-associated antisynthetase syndrome (Jo-1 ASS). The aim of this retrospective study was…Abstract Number: 2363 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Adrenocorticotropic Hormone Gel (Acthar Gel ®) in Refractory Dermatomyositis or Polymyositis
Background/Purpose: Adrenocorticotropic hormone (ACTH) gel (repository corticotropin injection) is a long-acting full sequence ACTH that may include other pro-opiomelanocortin peptides thought to have anti-inflammatory and…Abstract Number: 2364 • 2015 ACR/ARHP Annual Meeting
Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme a Reductase Positive Myopathy Patients without Statin Exposure May Have a Progressive Disease That Worsens Despite Aggressive Immunosuppressive Therapy
Background/Purpose: While the majority of myopathy patients with antibodies recognizing H 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) have had a statin exposure, approximately one third have not. In…Abstract Number: 2365 • 2015 ACR/ARHP Annual Meeting
Use of Long Term Subscutaneous Immunoglobulins in Inflammatory Myopathies: A Retrospective Analysis of 19 Patients
Background/Purpose: Intravenous immunoglobulin (IVIg) therapy is recommended for patients suffering from inflammatory myopathies refractory to corticosteroids and immunosuppressive drugs. It is also recommended for patients…Abstract Number: 2366 • 2015 ACR/ARHP Annual Meeting
The Anti-MDA5 Autoantibody Phenotype: Defining Clinical, Biochemical and Radiological Features Suggestive of Anti-MDA5-Associated Rapidly Progressive Interstitial Lung Disease
Background/Purpose: Anti-MDA5 autoantibody associated syndrome is a novel entity within the spectrum of autoimmune myositis. It has been described as a clinical mimic of the…Abstract Number: 2367 • 2015 ACR/ARHP Annual Meeting
Risk of Malignancy in Dermatomyositis with Anti-CADM-140/ Melanoma Differentiation- Associated Gene 5 Autoantibody
Background/Purpose: Anti-CADM-140/ Melanoma Differentiation-Associated Gene 5 (MDA5) antibody is found specifically in patients with dermatomyositis (DM). This autoantibody is associated with clinically amyopathic DM (CADM)…Abstract Number: 2368 • 2015 ACR/ARHP Annual Meeting
Myositis Specific-Autoantibodies: Predictors of Short-Term Good Outcome in Rituximab Treated-Refractory Idiopathic Inflammatory Myopathies
Background/Purpose: The treatment of idiopathic inflammatory myopathies (IIM) is challenging, complicated by its rarity and heterogeneity. Currently few studies have suggested the efficacy of RTX…Abstract Number: 2369 • 2015 ACR/ARHP Annual Meeting
Dermatomyositis Associated with Anti-Melanoma Differentiation-Associated Gene 5 Antibodies: A Longitudinal Analysis
Background/Purpose: Dermatomyositis (DM) patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibodies are at increased risk of developing interstitial lung disease (ILD). The natural history of…Abstract Number: 2370 • 2015 ACR/ARHP Annual Meeting
Clinical Characteristics of Anti-MDA5 (+) Dermatomyositis Patients in North America
Background/Purpose: Clinically amyopathic dermatomyositis (CADM) patients have the classic rash (es) of DM but no objective proximal muscle weakness. Asian studies report a unique clinical phenotype in anti-MDA5…Abstract Number: 2371 • 2015 ACR/ARHP Annual Meeting
The Clinical Features of Recurrent Interstitial Lung Disease in Dermatomyositis Patients with Anti- Melanoma Differentiation-Associated Gene 5 Antibody
Background/Purpose: Interstitial lung disease (ILD) is the most common cause of mortality in polymyosytis (PM) and dermatomyositis (DM). It is well known that the DM…Abstract Number: 2372 • 2015 ACR/ARHP Annual Meeting
Timing of Onset and Cluster with Other Manifestations Influence the Spectrum of Arthritis in Anti Jo-1 Positive Antisynthetase Syndrome: Results from a Multicenter, International, Retrospective Study
Background/Purpose: arthritis, myositis and interstitial lung disease (ILD) are reported in up to 90% of patients affected by antisynthetase syndrome (ASSD) and thus represent the…Abstract Number: 2373 • 2015 ACR/ARHP Annual Meeting
Frequency of Antinuclear (ANA), Myositis-Specific (MSA) and Myositis-Associated Antibodies (MAA) in Patients with Idiopathic Inflammatory Myopathies (IIM) from Mexico, Central and South America Centers: Data from the Panlar Myositis Study Group.
Background/Purpose: Dermatomyositis (DM) and polymyositis (PM) are forms of IIM that involve skeletal muscle as well as many other organs. As in other systemic rheumatic…Abstract Number: 2374 • 2015 ACR/ARHP Annual Meeting
Pulmonary Arterial Hypertension in Patients with Anti-PM-Scl Antibody
Background/Purpose: Pulmonary arterial hypertension (PAH) may be a disease manifestation of patients with anti-PM-Scl antibody (PM-Scl). In the 2014 ACR annual meeting we reported significantly…
ACR Meeting Abstracts